Last reviewed · How we verify

Sleepiness Due To Obstructive Sleep Apnea — Treatment Landscape & Competitive Intelligence

Sleepiness Due To Obstructive Sleep Apnea (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sleepiness Due To Obstructive Sleep Apnea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nuvigil ARMODAFINIL Nuvo Pharms armodafinil D(2) dopamine receptor 2007-01-01
Provigil modafinil Nuvo Pharms Sympathomimetic-like Agent [EPC] D(2) dopamine receptor 1998-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Nuvo Pharms · 2 drugs in Sleepiness Due To Obstructive Sleep Apnea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sleepiness Due To Obstructive Sleep Apnea:

Cite this brief

Drug Landscape (2026). Sleepiness Due To Obstructive Sleep Apnea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sleepiness-due-to-obstructive-sleep-apnea. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing